Ironwood Pharma (IRWD) Tops Q4 EPS by 7c
FREE Breaking News Alerts from StreetInsider.com!
StreetInsider.com Top Tickers, 8/14/2026
- S&P 500 notches record-high close as rate-hike worries ease
- Oil settles down 2% on weak demand outlook, hefty US crude build
- BofA lifts server CPU TAM to $210bn+ on the rise of AI agents
- Burry doubles down on Nebius short after stock surges 34% on earnings
- JPMorgan gets bullish on Salesforce, says concerns are "overblown"
Ironwood Pharmaceuticals Provides Fourth Quarter and Full Year 2015 Investor Update
February 18, 2016 4:05 PM ESTKey advancements within three blockbuster opportunities: IBS-C/CIC, vascular/fibrotic diseases and refractory GERD
LINZESS® (linaclotide) U.S. net sales increased ~53% to $455 million in 2015; on track to exceed $1 billion in net sales by 2020
Ironwood revenue increased >95% to $150 million in 2015, primarily driven by continued growth in LINZESS net sales and expansion in commercial margin to ~46%
Delivered on 2015 financial guidance with strong business execution
CAMBRIDGE, Mass.--(BUSINESS WIRE)--... More
